Drug Repurposing for the Management of Depression: Where Do We Stand Currently?

Total Page:16

File Type:pdf, Size:1020Kb

Drug Repurposing for the Management of Depression: Where Do We Stand Currently? life Review Drug Repurposing for the Management of Depression: Where Do We Stand Currently? Hosna Mohammad Sadeghi 1,†, Ida Adeli 1,† , Taraneh Mousavi 1,2, Marzieh Daniali 1,2, Shekoufeh Nikfar 3,4,5 and Mohammad Abdollahi 1,2,* 1 Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417614411, Iran; [email protected] (H.M.S.); [email protected] (I.A.); [email protected] (T.M.); [email protected] (M.D.) 2 Department of Toxicology and Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Tehran 1417614411, Iran 3 Personalized Medicine Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran 1417614411, Iran; [email protected] 4 Pharmaceutical Sciences Research Center (PSRC) and the Pharmaceutical Management and Economics Research Center (PMERC), Evidence-Based Evaluation of Cost-Effectiveness and Clinical Outcomes Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417614411, Iran 5 Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran 1417614411, Iran * Correspondence: [email protected] † Equally contributed as first authors. Citation: Mohammad Sadeghi, H.; Abstract: A slow rate of new drug discovery and higher costs of new drug development attracted Adeli, I.; Mousavi, T.; Daniali, M.; the attention of scientists and physicians for the repurposing and repositioning of old medications. Nikfar, S.; Abdollahi, M. Drug Experimental studies and off-label use of drugs have helped drive data for further studies of ap- Repurposing for the Management of proving these medications. A deeper understanding of the pathogenesis of depression encourages Depression: Where Do We Stand novel discoveries through drug repurposing and drug repositioning to treat depression. In addition Currently? Life 2021, 11, 774. to reducing neurotransmitters like epinephrine and serotonin, other mechanisms such as inflam- https://doi.org/10.3390/ mation, insufficient blood supply, and neurotoxicants are now considered as the possible involved life11080774 mechanisms. Considering the mentioned mechanisms has resulted in repurposed medications to treat treatment-resistant depression (TRD) as alternative approaches. This review aims to discuss the Academic Editors: Anna Serefko, Ewa Poleszak and Aleksandra Szopa available treatments and their progress way during repositioning. Neurotransmitters’ antagonists, atypical antipsychotics, and CNS stimulants have been studied for the repurposing aims. However, Received: 29 June 2021 they need proper studies in terms of formulation, matching with regulatory standards, and efficacy. Accepted: 26 July 2021 Published: 30 July 2021 Keywords: clinical trials; depression; major depressive disorder; new drugs; repurposing; reposition- ing; strategies Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affil- iations. 1. Introduction Despite the high rate of technological progress and improvements in knowledge of different diseases, the discovery of new medications demonstrated a lower speed [1]. As the regulatory requirements for bringing a new medication to the market is becom- Copyright: © 2021 by the authors. ing more challenging to meet, medication cost increases globally [2]. Licensee MDPI, Basel, Switzerland. Drug repositioning, also called drug repurposing or re-tasking, is a promising strategy This article is an open access article to introduce new indications for other therapeutic goals for an available drug in the distributed under the terms and market [3]. Since the safety profile of these medications was studied thoroughly before, conditions of the Creative Commons the development of their formulation has been analyzed, and the medicines successfully Attribution (CC BY) license (https:// passed the preclinical and clinical steps, the risk of failure decreases significantly [4]. To creativecommons.org/licenses/by/ apply a drug repositioning strategy, three main steps are needed to be concluded; first, a 4.0/). Life 2021, 11, 774. https://doi.org/10.3390/life11080774 https://www.mdpi.com/journal/life Life 2021, 11, 774 2 of 35 molecule/substance should be suggested for the mentioned indication; second, preclinical models, including animal and computational models, should be assessed and last the efficacy of medication should be analyzed [5]. As a significant mental disorder, major depressive disorder (MDD) affects approxi- mately 264 million globally [6]. Due to the insufficient therapeutic response of patients to the available medications, the need for new medicines has attracted scientists world- wide [7]. Various mechanisms have been associated with the prevalence of MDD, and these mechanisms directly influence medication selection. Changes in inflammatory biomarkers, neurotransmitters, age-related, and genetic factors are among the mechanisms constituting the indications of medications [8]. Moreover, new antidepressant medications usually act on multiple intra- and extra-cellular markers, indicating their poly-pharmacology indi- cations [9]. This review aims to provide a complete insight into the drug repositioning strategy, especially the candidates that could be beneficial in managing MDD. 2. Drug Repurposing 2.1. History Drug repurposing is the procedure of finding new indications for approved or in- vestigational medications [10,11]. Investigational medicines may have had a desirable safety profile in phase I/II clinical trials [12] but never reached the market [11,12] due to reasons unrelated to safety [12], such as lack of efficacy [11]. Drug repurposing can emerge in different forms like repositioning, reformulation, and combination [13,14]. Drug repurposing was serendipitous and accidental in the past; whenever a medication had shown an off-target or a new on-target effect, it was investigated for commercial exploita- tion. [10]. So far, the most successful repurposed drugs have been found accidentally, and no systematic approach has been involved in the process [10,15]. Sildenafil citrate was an antihypertensive medication that got repurposed as retrospective clinical data analysis showed its positive effect on erectile dysfunction [10,16]. The year sildenafil got marketed by Pfizer for erectile dysfunction under the name Viagra® [17], it held a 47% share of this problem’s market, and the total sales were USD 2.05 billion worldwide [10]. Thalidomide is another well-known instance causing many severe skeletal birth defections in children whose mothers had taken this medication during the first trimester of pregnancy [1,10]. In consequence, thalidomide was withdrawn for four years [10]. In 1964, thalidomide was fortuitously recognized to be effective in erythema nodosum leprosum (ENL) [18]. Decades later, in 1999, thalidomide was discovered to be effective in multiple myeloma [19]. The positive outcome in multiple myeloma led to further derivative developments like lenalidomide [10]. Bupropion, an antidepressant medication got approved by the United States Food and Drug Administration (US-FDA) for smoking cessation [13], botulinum toxin A, the compound used for eye muscle disorders with cosmetic impacts [18] and mi- noxidil, the antihypertensive medication, became established for pattern hair loss in male and female [17,20] are some instances of well-known repurposed drugs [12]. Iproniazid, an antitubercular compound, was the first medication got reported for its antidepressant effect. This compound showed euphoria, psychostimulation, increased appetite, and im- proved sleep as the side effects [21]. The story of finding D-lysergic acid diethylamide (LSD) psychedelic effects is another exciting example of serendipitous discovery in the field of psychiatry. LSD was first synthesized in 1938, but it did not show considerable physiological effects in animal testing. LSD’s strong and extraordinary influences on the mind were accidentally discovered for the first time in 1943 [22]. Thirteen medications have been repurposed for depression or bipolar depression treatment by 2017 [13]. 2.2. Different Types of Drug Repurposing Drug reformulation, repositioning, and combination are counted as different drug repurposing/repositioning [13,14]. Life 2021, 11, 774 3 of 35 2.2.1. Drug Repositioning It finds new indications for a medication that already has other therapeutic indica- tions [13,14]. For instance, mifepristone, an anti-progesterone drug with an initial indication for abortion, was experimentally effective in psychotic depression [3,23]. 2.2.2. Drug Reformulation It is about using a medication in a new dosage form [13,14]. The new formulation can both be taken via the same old route or a different route of administration. An example of drug reformulation is formulating ketamine for intranasal and sublingual routes to treat MDD [13]. 2.2.3. Drug Combination It refers to using two or more medications together [13,14] to improve efficacy and safety [13]. For example, using quetiapine and antidepressants in combination leads to the increased effect of antidepressant medications in the elderly suffering from MDD and cerebrovascular deterioration. In addition, taking anti-inflammatory medicines with antidepressants enhances responses to first-line antidepressants [13]. 2.3. Common Approaches Before the development stage
Recommended publications
  • Domains: 1. Optimizing Medication Use, Using Front- and Back Office Strategies 2
    A SUPPLEMENTARY TABLES Table S1: Domains and themes in the action plan of the Belgian Government (2015-2020) Domains: 1. Optimizing medication use, using front- and back office strategies 2. Continuity of pharmacotherapy in light of transmural care 3. Scientific skills of the hospital pharmacist 4. Transfer of information to and communication with the patient Themes: 2015: anchoring the minimal conditions for the application of clinical pharmacy 2016: development of a structured method for the anamnesis, registration and communication of the medication on admission and discharge 2017: application of clinical pharmacy for specific therapies 2018: application of risk screening for patient groups 2019: application of risk screening for medication groups or pathologies 2020: evaluation of the development of clinical pharmacy in the Belgian hospitals and evaluation of the action plan 2015-2020 Table S2: Anatomical and therapeutic classes of the drugs involved in the discrepancies detected after medication reconciliation n (%) Example(s) of discrepancy Gastro-intestinal system 43 (35.2%) antacids 6 O: antacid PRN antihistaminics 1 O: ranitidine 150 mg 1 pd proton pump inhibitors 5 O: pantoprazole 20 mg 1 pd propulsives 3 O: domperidone PRN; N: alizapride laxatives 9 O: macrogol PRN or 1 pd, bisacodyl PRN or 1 pd antipropulsives 2 O: loperamide 1 pd probiotics 1 O: frequent need for probiotics antidiabetics 1 D: dose repaglinide unknown multivitamins 5 O: multivitamins 1 pd vitamin D 5 O: vitamin D 1 per week vitamin B 2 N: vitamin B complex
    [Show full text]
  • PROZAC Product Monograph Page 1 of 49 Table of Contents
    PRODUCT MONOGRAPH PrPROZAC® fluoxetine hydrochloride 10 mg and 20 mg Capsules Antidepressant / Antiobsessional / Antibulimic © Eli Lilly Canada Inc. Date of Revision: January, 25 Exchange Tower 2021 130 King Street West, Suite 900 PO Box 73 Toronto, Ontario M5X 1B1 1-888-545-5972 www.lilly.ca Submission Control No: 192639 PROZAC Product Monograph Page 1 of 49 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .......................................................3 SUMMARY PRODUCT INFORMATION...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS .....................................................................................................4 WARNINGS AND PRECAUTIONS ....................................................................................5 ADVERSE REACTIONS ...................................................................................................13 DRUG INTERACTIONS....................................................................................................22 DOSAGE AND ADMINISTRATION ................................................................................27 OVERDOSAGE..................................................................................................................28 ACTION AND CLINICAL PHARMACOLOGY ...............................................................30 STORAGE AND STABILITY............................................................................................32
    [Show full text]
  • HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Metabolic Changes: Atypical antipsychotic drugs have been associated with These highlights do not include all the information needed to use metabolic changes that may increase cardiovascular/cerebrovascular risk. CLOZARIL safely and effectively. See full prescribing information for These metabolic changes include: CLOZARIL. o Hyperglycemia and Diabetes Mellitus: Monitor for symptoms of CLOZARIL® (clozapine) tablets, for oral use hyperglycemia including polydipsia, polyuria, polyphagia, and Initial U.S. Approval: 1989 weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes. (5.9) WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC o Dyslipidemia: Undesirable alterations in lipids have occurred in HYPOTENSION, BRADYCARDIA, AND SYNCOPE; SEIZURE; patients treated with atypical antipsychotics. (5.9) MYOCARDITIS AND CARDIOMYOPATHY; INCREASED o Weight Gain: Significant weight gain has occurred. Monitor weight MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA- gain. (5.9) RELATED PSYCHOSIS • Neuroleptic Malignant Syndrome (NMS): Immediately discontinue and See full prescribing information for complete boxed warning. monitor closely. Assess for co-morbid conditions. (5.10) • Fever: Evaluate for infection and for neutropenia, NMS. (5.11) • Pulmonary Embolism (PE): Consider PE if respiratory distress, chest pain, • Severe Neutropenia: CLOZARIL can cause severe neutropenia, which or deep-vein thrombosis occur. (5.12) can lead to serious and fatal infections. Patients initiating and • Anticholinergic Toxicity: Use cautiously in presence of specific conditions continuing treatment with CLOZARIL must have a baseline blood (e.g., narrow angle glaucoma, use of anticholinergic drugs). (5.13) absolute neutrophil count (ANC) measured before treatment initiation • Interference with Cognitive and Motor Performance: Advise caution when and regular ANC monitoring during treatment (2.1, 5.1).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • The Neuroprotective Effects of Melatonin: Possible Role in the Pathophysiology of Neuropsychiatric Disease
    brain sciences Perspective The Neuroprotective Effects of Melatonin: Possible Role in the Pathophysiology of Neuropsychiatric Disease Jung Goo Lee 1,2 , Young Sup Woo 3, Sung Woo Park 2,4, Dae-Hyun Seog 5, Mi Kyoung Seo 6 and Won-Myong Bahk 3,* 1 Department of Psychiatry, College of Medicine, Haeundae Paik Hospital, Inje University, Busan 47392, Korea; [email protected] 2 Paik Institute for Clinical Research, Department of Health Science and Technology, Graduate School, Inje University, Busan 47392, Korea; [email protected] 3 Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul 07345, Korea; [email protected] 4 Department of Convergence Biomedical Science, College of Medicine, Inje University, Busan 47392, Korea 5 Department of Biochemistry, College of Medicine, Inje University, Busan 47392, Korea; [email protected] 6 Paik Institute for Clinical Research, Inje University, Busan 47392, Korea; [email protected] * Correspondence: [email protected] Received: 16 September 2019; Accepted: 19 October 2019; Published: 21 October 2019 Abstract: Melatonin is a hormone that is secreted by the pineal gland. To date, melatonin is known to regulate the sleep cycle by controlling the circadian rhythm. However, recent advances in neuroscience and molecular biology have led to the discovery of new actions and effects of melatonin. In recent studies, melatonin was shown to have antioxidant activity and, possibly, to affect the development of Alzheimer’s disease (AD). In addition, melatonin has neuroprotective effects and affects neuroplasticity, thus indicating potential antidepressant properties. In the present review, the new functions of melatonin are summarized and a therapeutic target for the development of new drugs based on the mechanism of action of melatonin is proposed.
    [Show full text]
  • Viewed the Existence of Multiple Muscarinic CNS Penetration May Occur When the Blood-Brain Barrier Receptors in the Mammalian Myocardium and Have Is Compromised
    BMC Pharmacology BioMed Central Research article Open Access In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine G Howell III†1, L West†1, C Jenkins2, B Lineberry1, D Yokum1 and R Rockhold*1 Address: 1Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS 39216, USA and 2Tougaloo College, Tougaloo, MS, USA Email: G Howell - [email protected]; L West - [email protected]; C Jenkins - [email protected]; B Lineberry - [email protected]; D Yokum - [email protected]; R Rockhold* - [email protected] * Corresponding author †Equal contributors Published: 18 August 2005 Received: 06 October 2004 Accepted: 18 August 2005 BMC Pharmacology 2005, 5:13 doi:10.1186/1471-2210-5-13 This article is available from: http://www.biomedcentral.com/1471-2210/5/13 © 2005 Howell et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Muscarinic receptor mediated adverse effects, such as sedation and xerostomia, significantly hinder the therapeutic usefulness of first generation antihistamines. Therefore, second and third generation antihistamines which effectively antagonize the H1 receptor without significant affinity for muscarinic receptors have been developed. However, both in vitro and in vivo experimentation indicates that the third generation antihistamine, desloratadine, antagonizes muscarinic receptors. To fully examine the in vivo antimuscarinic efficacy of desloratadine, two murine and two rat models were utilized. The murine models sought to determine the efficacy of desloratadine to antagonize muscarinic agonist induced salivation, lacrimation, and tremor.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Histamine Receptors
    Tocris Scientific Review Series Tocri-lu-2945 Histamine Receptors Iwan de Esch and Rob Leurs Introduction Leiden/Amsterdam Center for Drug Research (LACDR), Division Histamine is one of the aminergic neurotransmitters and plays of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit an important role in the regulation of several (patho)physiological Amsterdam, De Boelelaan 1083, 1081 HV, Amsterdam, The processes. In the mammalian brain histamine is synthesised in Netherlands restricted populations of neurons that are located in the tuberomammillary nucleus of the posterior hypothalamus.1 Dr. Iwan de Esch is an assistant professor and Prof. Rob Leurs is These neurons project diffusely to most cerebral areas and have full professor and head of the Division of Medicinal Chemistry of been implicated in several brain functions (e.g. sleep/ the Leiden/Amsterdam Center of Drug Research (LACDR), VU wakefulness, hormonal secretion, cardiovascular control, University Amsterdam, The Netherlands. Since the seventies, thermoregulation, food intake, and memory formation).2 In histamine receptor research has been one of the traditional peripheral tissues, histamine is stored in mast cells, eosinophils, themes of the division. Molecular understanding of ligand- basophils, enterochromaffin cells and probably also in some receptor interaction is obtained by combining pharmacology specific neurons. Mast cell histamine plays an important role in (signal transduction, proliferation), molecular biology, receptor the pathogenesis of various allergic conditions. After mast cell modelling and the synthesis and identification of new ligands. degranulation, release of histamine leads to various well-known symptoms of allergic conditions in the skin and the airway system. In 1937, Bovet and Staub discovered compounds that antagonise the effect of histamine on these allergic reactions.3 Ever since, there has been intense research devoted towards finding novel ligands with (anti-) histaminergic activity.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Prozac and Prozac Weekly (Fluoxetine Hcl)
    CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: APPLICATION NUMBER: NDA 18-936/S-093 NDA 21-235/S-016 Trade Name: Prozac and Prozac Weekly Generic Name: fluoxetine HCl Sponsor: Lilly Approval Date: April 4, 2011 ,QGLFDWLRQ Revisions to the following section 8.1 of the label. CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: NDA 18-936/S-093 NDA 21-235/S-016 CONTENTS Reviews / Information Included in this NDA Review. Approval Letter X Other Action Letters X Labeling Summary Review X Officer/Employee List Office Director Memo Cross Discipline Team Leader Review Medical Review(s) X Chemistry Review(s) Pharmacology Review(s) Statistical Review(s) Clinical Pharmacology/Biopharmaceutics Review(s) Other Reviews X Proprietary Name Review(s) Administrative/Correspondence Document(s) X CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: NDA 18-936/S-093 NDA 21-235/S-016 APPROVAL LETTER DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 018936/S-091/S-093/S-095 NDA 021235/S-015/S-016/S-017 SUPPLEMENT APPROVAL Eli Lilly & Company Attention: Kevin C. Sheehan, MS, Pharm.D. Manager, Global Regulatory Affairs - US Lilly Corporate Center Indianapolis, IN 46285 Dear Dr. Sheehan: Please refer to your Supplemental New Drug Applications (sNDA) dated and received May 21, 2009 (018936/S-091 and 021235/S-015), November 6, 2009 (018936/S-093 and 021235/S-016), and April 14, 2010 (018936/S-095 and 021235/S-017), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Prozac (fluoxetine hydrochloride) 10 mg, 20 mg, and 40 mg capsules and Prozac Weekly (fluoxetine hydrochloride) 90 mg delayed-release capsules.
    [Show full text]
  • Management of Major Depressive Disorder Clinical Practice Guidelines May 2014
    Federal Bureau of Prisons Management of Major Depressive Disorder Clinical Practice Guidelines May 2014 Table of Contents 1. Purpose ............................................................................................................................................. 1 2. Introduction ...................................................................................................................................... 1 Natural History ................................................................................................................................. 2 Special Considerations ...................................................................................................................... 2 3. Screening ........................................................................................................................................... 3 Screening Questions .......................................................................................................................... 3 Further Screening Methods................................................................................................................ 4 4. Diagnosis ........................................................................................................................................... 4 Depression: Three Levels of Severity ............................................................................................... 4 Clinical Interview and Documentation of Risk Assessment...............................................................
    [Show full text]